Navigation Links
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Date:6/20/2008

co-primary endpoints were changes in pulmonary vascular resistance (PVR) and exercise capacity (6MWD). Disease progression was assessed by the secondary endpoints time to clinical worsening and WHO functional class.

A highly significant reduction in PVR of 22.6% (p <0.0001) and a significant 77% risk reduction in delaying the time to clinical worsening (p = 0.011) were seen after six months of bosentan treatment compared with placebo. Time to clinical worsening, defined by death, hospitalization for PAH and symptomatic progression of PAH, showed that more patients remained stable without signs of deterioration in the bosentan-treated group compared with placebo (3.4% vs. 13.2%, p = 0.029). In addition, a significant delay in WHO functional class deterioration was observed in the bosentan group compared with placebo, providing further evidence of delayed disease progression. The improvement in 6MWD did not reach statistical significance (p = 0.076). This may reflect the fact that, on average, patients in EARLY had a relatively well-preserved exercise capacity, which therefore can be more difficult to improve.

The safety and tolerability profile of bosentan was consistent with that observed in previous placebo-controlled clinical trials.(2, 3)

Professor Gerald Simonneau, Hopital Antoine Beclere, Universite Paris-Sud, France commented: "The results from EARLY show the relentlessly progressive nature of PAH, even in its early stages. It is of paramount importance to screen high risk patients to attain a timely diagnosis and then to treat these patients with an evidence-based approach. It is also crucial that all PAH patients, regardless of functional class, are routinely monitored for the earliest signs and symptoms of PAH progression."

A subgroup of patients who received concomitant sildenafil showed improvements in PVR and 6MWD consistent with the overall results.

Further evidence of the effect of bosentan on hemodynamics is provide
'/>"/>

SOURCE Actelion Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
2. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
9. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
10. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
11. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  A new analysis of Centers for ... enrollment data shows that 81 percent of seniors chose ... extra discounts at certain pharmacies. The findings were released ... plans are now the foundation of Medicare Part D," ...
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier ... stem cells, reported results for the second quarter of fiscal ... the Company reported revenues of $5.9 million, which compares with ... ago. Disposable revenues in the second quarter of fiscal 2011 ...
... 10, 2011 Cambrex Corporation (NYSE: CBM ) reports ... 31, 2010. Highlights ... currency, sales increased 9.2% compared to fourth quarter 2009. Adjusted ... of 54% compared to $9.4 million of EBITDA in the fourth ...
Cached Medicine Technology:ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 2ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 3ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 4ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 5ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 6ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 2Cambrex Reports Fourth Quarter and Full Year 2010 Results 3Cambrex Reports Fourth Quarter and Full Year 2010 Results 4Cambrex Reports Fourth Quarter and Full Year 2010 Results 5Cambrex Reports Fourth Quarter and Full Year 2010 Results 6Cambrex Reports Fourth Quarter and Full Year 2010 Results 7Cambrex Reports Fourth Quarter and Full Year 2010 Results 8Cambrex Reports Fourth Quarter and Full Year 2010 Results 9
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... analytics, and clinical business intelligence solutions today announced that it is working with Oracle to further the goals of improving quality of care reporting and patient safety ... ... ... ...
... ... that builds open source platforms and develops advanced research solutions, has ... totaling more than $600,000 to focus research efforts on developing approach-specific, ... is to work towards an interactive simulator that replicates future neurosurgery ...
... BOSTON Improving on traditional screening tests for potential ... developed a laboratory technique that more closely simulates ... with the body,s normal cells. Because these neighboring ... as the "tumor microenvironment" can alter the ...
... exam, study finds , SUNDAY, March 14 (HealthDay News) -- ... and collegiate hockey players in a U.S. study had abnormal ... see if abnormal MRI results are found incidentally in active ... the department of family medicine and orthopedics at Hershey Medical ...
... below currently recommended levels did not significantly ... disease events in adults with type 2 diabetes who ... according to new results from the landmark Action to ... treating multiple blood lipids with combination drug therapy of ...
... NEW YORK, NY AND ATLANTA, GA MARCH 13, ... EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass ... compare drug-eluting stents to coronary artery bypass graft surgery ... made today at "Optimizing PCI Outcomes: Evolving Paradigms," a ...
Cached Medicine News:Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 2Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 3Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 4Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 2Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 3Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery 2
... The RSV ASR contains primers and a ... Respiratory Syncytial Virus (RSV). In addition, this ... probe for a,separate sample processing control. This ... FAM and Texas Red reporter dyes such ...
Digital Ultrasonic Diagnostic Imaging System...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Pefakit PiCT LMWH Controls...
Medicine Products: